The 2017 Chinese Pharmaceutical Industry Development Summit Forum was held in Kunming on June 20. The “most influential” lists for the Chinese pharmaceutical industry in 2016 were released at the meeting. Hansoh Pharma ranked No. 22 among the “100 Top Enterprises in Chinese Pharmaceutical Industry”.
It was reported that the 2017 Chinese Pharmaceutical Industry Development Summit Forum was sponsored by All-China Federation of Industry and Commerce Medical Pharmaceutical Chamber and Yunnan Provincial Science and Technology Department. More than 750 pharmaceutical industry entrepreneurs, experts and scholars from all over the country attended the forum for in-depth discussions on the themes of “implementing national strategy, promoting industry cooperation and creating a bright future for the pharmaceutical industry”.
As one of the leaders in innovative drug R&D in China, Hansoh Pharma continues to devote a high share of its investment to innovative drug R&D, while introducing international high-end drugs and making drugs more accessible to Chinese people, with the aim of providing drug security for the cause of improving people’s health care in China. On this basis, the Company has achieved great business development, steadily increased its overall strength and gradually enhanced its influence at home and abroad.
Research and Development
The Company has established R&D centers in Lianyungang and in Zhangjiang, Shanghai, and owns several R&D platforms, including a national-level enterprise technical center, a national-level post-doctoral research center, a Jiangsu provincial research center for digestive tract drug engineering technology, a key laboratory for biological pharmaceutical high technology research of Jiangsu province, a National & Local Joint Engineering Research Center and an enterprise academician workstation.
The Company has undertaken more than 40 national-level projects, including Program 863, National Science and Technology Major Projects for “development of important new drugs” and National Torch Plan. It has nearly 50 ongoing projects for development of category 1 new drugs, in which more than 10 projects have entered the clinical research stage.
The Company pays great attention to the introduction and fostering of talent. It has more than 1000 R&D employees, of whom holders of master’s degrees and PhDs and engineers with senior technical titles account for more than 50%. It also has a talent team led by the high-end talents from the Jiangsu innovative and entrepreneurial talent program and talent program 333 of Jiangsu.
Quality
The Company has established a first-rate quality management and control system based on the quality guideline of “full participation, full process and continuous improvement” as well as the concept of “quality by design”, and it has built a modern preparation industry park according to EU standards and introduced world-class production facilities to provide hardware guarantees for outstanding quality.
International development
The Company’s anti-tumor preparations passed FDA certification in 2012 and were exported to international mainstream pharmaceutical markets, including Europe and USA. Currently, 6 Hansoh Pharma preparations and 8 of its bulk drugs are sold in more than 30 countries and regions. The Company is now accelerating the internationalization of its innovative drugs and carrying out multi-center clinical trials around the world.
In the past 20 years, Hansoh Pharma has responded actively to calls from national policies and embraced the corporate mission of “serving the society and promoting health”, with an aim to become a pioneer in scientific & technical innovation and international development in China’s pharmaceutical industry.
Toward that goal, Hansoh Pharma is now combining its forces all over the world and working hard to realize the “Hansoh Dream, Health Dream”. In the future, an innovative international pharmaceutical enterprise group will take shape with a new stature, ready to contribute the wisdom and power of Hansoh so that the cause of human health can make ever greater strides.
